Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications IgAN

Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy

View
Publications FSGS

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

View
Publications Nephrology

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults

View
Publications IgAN

Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

View
Publications IgAN

Sparsentan Is Superior to Losartan in the gddY Mouse Model 1 of IgA Nephropathy

View
Publications Nephrology

Physiologically-Based Pharmacokinetic Model of Sparsentan to Evaluate Drug-Drug Interaction Potential

View
Medical Information IgAN

FILSPARI (sparsentan) Prescribing Information Update

Learn more
Publications IgAN

Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile

View
Publications IgAN Nephrology

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial

View
Publications FSGS

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

View
Medical Information IgAN

FILSPARI (sparsentan): Impact on Male Fertility

Learn more
Medical Information IgAN

FILSPARI (sparsentan): Use in Transplant Patients

Learn more
Medical Information IgAN

FILSPARI  (sparsentan): Use in Patients With Severely Decreased eGFR in IgA Nephropathy

Learn more